The signing of the HOA and MOU by CytoMed Therapeutics indicates a proactive approach to expanding its research capabilities and potentially bringing new cancer therapies to market. This news is likely to be viewed positively by investors as it demonstrates the company's commitment to growth and innovation in the biopharmaceutical industry. The direct involvement in advancing allogeneic Gamma Delta T Cell technology could lead to significant developments in cancer treatment, which may have a positive impact on the company's stock price in the short term.